title: The role of the Sysmex SE9000 immature myeloid index and Sysmex R2000 reticulocyte parameters in optimizing the timing of peripheral blood stem cell harvesting in patients with lymphoma and myeloma.
abstract: Peripheral blood CD34/45+ cell (CD34/45) enumeration is an expensive and labour-intensive investigation but remains the standard assay for optimizing yield and timing of peripheral blood stem cell harvesting (PBSCH). The present study examined the value of the Sysmex SE9000 parameters (WBC, neutrophil count, and immature myeloid index (IMI)) and Sysmex R2000 reticulocyte parameters (absolute, high and medium fluorescence reticulocytes) in predicting the optimum timing of PBSCH in comparison to peripheral blood CD34/45. Sixty-four PBSCH from 23 patients with haematological malignancies were assessed with a variety of mobilization regimes used. Reticulocyte parameters showed high interpatient variability and did not prove clinically useful. IMI did not consistently predict satisfactory PBSCH yield except when > 1000 x 10(6)/l. Peripheral blood CD34/45 was the most useful predictor of yield. IMI > 20 x 10(6)/l was, however, a useful surrogate for predicting a rise in peripheral blood CD34/45 from nadir and proved to be superior to WBC or neutrophil count. A rising IMI is a marker of early regeneration and has a role in determining when to initiate enumeration of peripheral blood CD34/45.
authors.affiliation: Department of Haematology, Ninewells Hospital and Medical School, Dundee, UK.
authors.forename: I D
authors.initials: ID
authors.lastname: Gowans
authors.forename: M D
authors.initials: MD
authors.lastname: Hepburn
authors.forename: D M
authors.initials: DM
authors.lastname: Clark
authors.forename: G
authors.initials: G
authors.lastname: Patterson
authors.forename: P S
authors.initials: PS
authors.lastname: Rawlinson
authors.forename: D T
authors.initials: DT
authors.lastname: Bowen
mesh_terms: D001772:Blood Cell Count; D019650:Hematopoietic Stem Cell Mobilization; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells / Q000473:pathology; D006801:Humans; D008223:Lymphoma / Q000473:pathology* / Q000628:therapy; D009101:Multiple Myeloma / Q000473:pathology* / Q000628:therapy; D012156:Reticulocytes / Q000473:pathology*